INO241101C2500
- 0.00
- 0.000.00%
Inovio Pharmaceuticals Newsroom
Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times
INOVIO Presents Data on INO-3107's Immune Response Against HPV-6 and HPV-11
Express News | Inovio Pharmaceuticals Inc - Ino-3107 Well Tolerated, 81% of Patients Required Fewer Surgeries Post-Treatment
Express News | Inovio Announces New Data at Scientific Conferences for Lead Candidate, Ino-3107, as a Potential Treatment for Rrp
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Inovio Pharmaceuticals Analyst Ratings
RBC Cuts Price Target on Inovio Pharmaceuticals to $7 From $8, Keeps Sector Perform, Speculative Risk
INOVIO Reports Inducement Grants Under Inducement Plan
'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now
Express News | Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa
Express News | President Biden Will Announce Donation Of 1M MPox Vaccine Doses, At Least $500M To African Countries To Support Their Response To Outbreak
Express News | CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic
Shandong Jincheng Pharmaceutical Group (300233.SZ): The Drug Administration approved the global first HPV therapeutic vaccine VGX-3100 jointly developed by Easton Pharma and usa Inovio Pharmaceuticals for phase II clinical trial application for HPV-16/18-
On September 23, Gelunhui announced that Shandong Jincheng Pharmaceutical Group (300233.SZ) received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration on September 20, 2024, approving the phase II clinical trial application for the global first HPV therapeutic vaccine VGX-3100 developed jointly by Dongfang Yue and the USA Inovio Pharmaceuticals, Inc. for HPV-16/18-related anal precancerous lesions. This phase II clinical trial for HPV-16/18-related anal precancerous lesions.
'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA
INOVIO to Present at Upcoming Scientific Conference
Express News | US To Stay Committed In Bringing Mpox Outbreak Under Control
Express News | Morocco Records First Case Of Mpox
'First Delivery Of Mpox Vaccine Doses From The Commission Arrive Today In The Democratic Republic Of Congo' - European Commission
Express News | WHO Chief Tedros Says Mpox Vaccines Could Be Ready For Emergency Use Listing Within Two Weeks; Some Mpox Vaccines Expected To Arrive In Congo In The Next Few Days